Relapsed/refractory patients

ASCO 2019 | Phase Ib/IIa study of iberdomide, in combination with dexamethasone, in patients with RRMM


Our Co-Chair, Sagar Lonial, Winship Cancer Institute at Emory University, Atlanta, US discusses the highlights from the phase Ib/IIa study of iberdomide (IBER) + dexamethasone (dex) in patients with relapsed/refractory multiple myeloma (RRMM) during ASCO 2019 in Chicago, US. IBER is a new CELMoD, an immunomodulatory agent, is reported here to have clinical activity as a single agent, and in combination with dexamethasone. Approximately one third of patients respond to IBER + dex and IBER has been seen to combine well with other agents. Professor Lonial concludes this potential for response is promising in such a heavily pretreated population.